Brasilia, Nov 29 (EFE) .- The Brazilian National Health Surveillance Agency (Anvisa) approved this Monday a new drug for the treatment of HIV developed by the British laboratory GlaxoSmithKline.
The drug represents “an advance in the treatment of people who carry the virus that causes AIDS,” since “it brings together, in a daily dose, two antiretrovirals (lamivudine and dolutegravir sodium) that were not available in a single tablet,” said Anvisa. , the highest Brazilian health authority, in a statement.
“The possibility of single doses simplifies the treatment and adherence of patients,” the regulatory body remarked.
The drug “reduces the amount of HIV in the body, keeping it at a low level” and, in addition, “promotes an increase in the count of CD4 cells, a type of white blood cell that plays an important role” in having a healthy immune system , which helps fight infection.
Anvisa indicated that the drug may be used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection for adults and adolescents over 12 years of age, “without a history of prior or replacement antiretroviral therapy. to the current regimen in people with virological suppression “.
The endorsement of the Brazilian health agency comes after GlaxoSmithKline presented “efficacy and safety studies” that gathered “data that support the authorized indications.”